Author

S. E. Richardson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Assay:flow cytometry· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

A. Garcia-Gimenez· 2 shared B. Huntly· 2 shared A. Godsinia· 1 shared A. Illendula· 1 shared A. R. Fard· 1 shared C. Boiers· 1 shared C. K. Lopez· 1 shared C. Kapeni· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Garcia-Gimenez

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 2, 2023

Genetic or pharmacological inactivation of CREBBP sensitizes B-cell Acute Lymphoblastic Leukemia to Ferroptotic Cell Death upon BCL2 Inhibition

A. Garcia-Gimenez, J. E. Ditcham, D. M. A. Azazi…·S. E. Richardson

This study identifies CREBBP mutations as a targetable vulnerability in B-ALL, showing that CREBBP inhibition sensitizes these cells to Venetoclax-induced ferroptosis.

DOI 10.1101/2023.10.02.556536

humanbulk RNA-seq

𝕏 PostBluesky

Cell BiologybioRxivPreprintSep 1, 2022

LGR5 targeting molecules as therapeutic agents for multiple cancer types

H.-C. Chen, N. Mueller, K. Stott…·M. de la Roche

This study develops LGR5-targeting antibodies and therapeutics that effectively kill CRC, HCC, and pre-B ALL cancer cells while sparing normal tissues.

DOI 10.1101/2022.09.01.506182

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintDec 22, 2020

Cell cycle corruption in a preleukemic ETV6-RUNX1 model exposes RUNX1 addiction as a therapeutic target in acute lymphoblastic leukemia

J. P. Wray, E. M. Deltcheva, C. Boiers…·T. Enver

This study shows that RUNX1 addiction is a therapeutic target in acute lymphoblastic leukemia, as inhibiting RUNX1 activity spares normal hematopoiesis and affects multiple genetic subtypes.

DOI 10.1101/2020.12.22.423823

humanChIP-seq

𝕏 PostBluesky